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Abstract
Background: Rearrangement of the short arm of chromosome 8 (8p) is very common in epithelial
cancers such as breast cancer. Usually there is an unbalanced translocation breakpoint in 8p12 (29.7
Mb – 38.5 Mb) with loss of distal 8p, sometimes with proximal amplification of 8p11-12.
Rearrangements in 8p11-12 have been investigated using high-resolution array CGH, but the first
30 Mb of 8p are less well characterised, although this region contains several proposed tumour
suppressor genes.
Methods: We analysed the whole of 8p by array CGH at tiling-path BAC resolution in 32 breast
and six pancreatic cancer cell lines. Regions of recurrent rearrangement distal to 8p12 were further
characterised, using regional fosmid arrays. FISH, and quantitative RT-PCR on over 60 breast
tumours validated the existence of similar events in primary material.
Results: We confirmed that 8p is usually lost up to at least 30 Mb, but a few lines showed focal
loss or copy number steps within this region. Three regions showed rearrangements common to
at least two cases: two regions of recurrent loss and one region of amplification. Loss within 8p23.3
(0 Mb – 2.2 Mb) was found in six cell lines. Of the genes always affected, ARHGEF10 showed a point
mutation of the remaining normal copies in the DU4475 cell line. Deletions within 12.7 Mb – 19.1
Mb in 8p22, in two cases, affected TUSC3. A novel amplicon was found within 8p21.3 (19.1 Mb –
23.4 Mb) in two lines and one of 98 tumours.
Conclusion: The pattern of rearrangements seen on 8p may be a consequence of the high density
of potential targets on this chromosome arm, and ARHGEF10 may be a new candidate tumour
suppressor gene.
Background
Rearrangements of the short arm of chromosome 8 (8p)
are one of the most common genetic events in breast [1-
3], pancreatic [4] and many other epithelial carcinomas
[5]. Although these rearrangements have been studied
using a variety of techniques, including cytogenetics, CGH
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LOH (loss of heterozygosity) analysis [1-4], their resolu-
tion, with the exception of studies on 8p12 which are dis-
cussed below, has been insufficient to provide a feasibly
small number of candidate genes for further analysis.
Loss of heterozygosity (LOH) studies suggest that there
are at least three tumour suppressor genes on 8p, in bands
8p23, 8p22, and 8p21, lost in several epithelial tumour
types [6-8]. The highest resolution of these studies is just
over 1 Mb, showing that bladder tumours have a common
region of LOH between microsatellite markers D8S504
(1.0 Mb) and D8S264 (2.1 Mb) in 8p23.3 [8]. In support
of this a lower resolution LOH study of ovarian adenocar-
cinomas identifies D8S264 (2.1 Mb) as showing the sec-
ond highest rate of LOH on 8p, with the highest rate at
D8S1827 (14.9 Mb) in 8p22 [7].
Cytogenetic and array CGH studies suggest that distal 8p
is frequently lost through an unbalanced translocation
that breaks in 8p11-12 [3,9]. The 8.8 Mb between 29.7 Mb
and 38.5 Mb, encompassing 8p12, is the only region of 8p
that has been extensively studied at high resolution, using
tiling-path BAC array CGH [10,11]. The translocation
breakpoints are usually within, or proximal to, the chro-
mosome band 8p12 and several of them are within the
NRG1 (neuregulin 1) gene (32.2 Mb; midpoint on NCBI
Build 36) [12,13]. Most recent research has focussed on
this breakpoint region and more proximal changes and
array CGH has not been applied to the distal candidate
regions identified by the earlier LOH studies.
The other known recurrent feature of 8p rearrangements,
at least in breast cancer, is amplification of 8p11-12 in
10–25% of cases, correlating with poor prognosis [11,13-
15]. This amplicon was originally suggested to target the
FGFR1 (Fibroblast Growth Factor Receptor 1) gene [16], a
member of the same family as FGFR2 (Fibroblast Growth
Factor Receptor 2), a known oncogene and driver of ampli-
fication. However, it has subsequently been shown that
FGFR1 is not always included in the minimal region of
amplification and other candidate oncogenes have been
suggested [11,13-15,17,18]. Detailed analysis of 8p11-12
amplification shows that there may be as many as four
sub-regions of amplification [11,17], raising the possibil-
ity that there are multiple cancer-relevant genes in 8p11-
12.
Array CGH studies at around 1 Mb resolution of breast
[19] and pancreatic cancer [20] confirm the general pat-
tern of loss of 8p but are of insufficient resolution to study
individual changes and identify candidate target genes.
Two tiling-path array CGH studies have been carried out
on seven [21] and ten [22] breast cancer cell lines. The first
mentions two changes on 8p [21]. MCF-7 has lost the
whole of 8p and T47D has two small deletions in 8p23.1,
although we now suggest that this is due to normal copy
number variation (see results). At least two further
changes – breaks at 8p12 with distal loss – are visible on
the ZR-75-30 and T47D karyograms included in the sup-
plementary data, but the raw data is not available for fur-
ther analysis. The second study identifies amplification of
8p11-12 in JIMT-1 [22].
Overall the picture of events occurring on 8p, and espe-
cially distal 8p, is rather confused, due at least in part to
the lack of high-resolution data on 8p rearrangements and
the lack of array CGH data for the regions highlighted by
LOH as likely to contain tumour suppressor genes. Array
CGH suggests that a tumour suppressor gene is located at,
or just distal to, the 8p12 breakpoint cluster [10], while
LOH analysis suggests the existence of several more distal
tumour suppressor genes [6-8]. In spite of recent analyses
that might suggest a relatively small overlap in alterations
across different tumour types [23], the general pattern of
changes on 8p is similar across several tumour types and
is therefore potentially driven by the same selective pres-
sures.
Our objectives were to investigate whether there were
recurrent events on 8p outside the well-studied 8p11-12
region; in particular to look for deletions in distal regions,
previously suggested by LOH to harbour a tumour sup-
pressor gene; and to try and make sense of the overall pat-
tern of changes seen on 8p. We set out to analyse the
whole of 8p by tiling-path-resolution array CGH in a
panel of breast cancer cell lines, and to investigate further
regions of recurrent rearrangement. We had previously
obtained SKY karyotypes for 27 of the 32 breast cancer cell
lines used in this study. Additionally we included six pan-
creatic cancer cell lines that show rearrangements of 8p at
cytogenetic resolution http://www.path.cam.ac.uk/
~pawefish/index.html.
Methods
Cell lines and primary tumours
Details of cancer cell lines can be found in Additional file
1. Immortalised human breast luminal epithelial line
HB4a [24] was obtained from Professor Mike O'Hare
(LICR/UCL Breast Cancer Laboratory, University College,
London, UK) and normal male lymphoblastoid line m62
obtained from Dr Chris Tyler-Smith (Wellcome Trust
Sanger Institute, Hinxton, UK). Both were cultured in
DMEM:F12 (Invitrogen, Paisley, UK).
All tumours were invasive breast carcinomas of small size
(91% < 3 cm) and low Nottingham Prognostic Index, col-
lected between 1990 and 1996 as part of the Nottingham/
Tenovus series [25-29]. 65% were ER positive. The tissue
microarray consisted of over 100 breast tumours. Match-Page 2 of 15
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available for 61 of these tumours.
Array construction
For the 8p tiling path array, 328 overlapping BAC clones
for the length of 8p were selected from the 32 k clone set
available from the BACPAC Resource Centre (CHORI, CA,
USA) [30]. Additional clones to close gaps were obtained
from Invitrogen and the Wellcome Trust Sanger Institute.
A subset of 6% of these BACs was sequenced to confirm
their identity. All except one matched their expected posi-
tion on the human genome. The remaining clone showed
evidence of containing more than one sequence and was
substituted on the final array. The selected overlapping
BAC clones for 8p provided an average clone spacing of
138 kb. A spot failure rate of around 10% resulted in an
actual resolution averaging 155 kb. For the fosmid array,
123 fosmids were obtained from the Sanger Institute,
mainly covering the regions of 8p21.3 (27 clones between
21.59 Mb and 22.25 Mb) and 8p22 (43 clones between
12.97 Mb and 15.68 Mb tiling three genes but not inter-
genic regions), identified by BAC array CGH as containing
multiple rearrangements, to a resolution of 0.04 Mb.
BACs were amplified by the method of Fiegler et al. [31]
and printed with the custom genomic 8p12 array first
described in Huang et al. [32] on CodeLink slides (Amer-
sham Biosciences, Amersham, UK). Fosmids were pre-
pared by the same method and printed as a separate array.
Array hybridisation
Array hybridisations were carried out essentially as
described in Garcia et al. [14] and Pole et al. [10]. Tumour
genomic DNA was labelled with Cy3-dCTP and a pool of
normal female genomic DNA with Cy5-dCTP (Amersham
Biosciences) using Bioprime labelling kits (Invitrogen).
Samples were hybridized to arrays overnight in the pres-
ence of Cot1 DNA (Invitrogen), and washed in PBS/
0.05% Tween-20 at room temperature, 50% formamide/
SSC at 42°C and then again in PBS/0.05% Tween-20.
Arrays were scanned on an Axon 4100A scanner with data
collected using GenePix Pro 4.1 software (Axon Instru-
ments, CA, USA) and analyzed in Excel. For array paint-
ing, chromosomes (provided by Dr Karen Howarth,
University of Cambridge, UK) were sorted by flow-cytom-
etry and amplified by GenomiPhi (GE Healthcare, Buck-
inghamshire, UK) according to the method of Howarth et
al. [33]. They were hybridised against GenomiPhi-ampli-
fied normal female genomic DNA.
The array performance was tested by self-self and male-
female hybridisations and using known 8p rearrange-
ments in T47D (Additional file 2). Self-self hybridisation
gave a standard deviation (SD) of ± 0.08 and male-female
hybridisation ± 0.04 SD. Log2 ratio shifts in response to
copy number changes were tested by hybridisation of
T47D against normal female gDNA. Copy number
changes were estimated by inspection, taking into account
both the shift in log2 ratio and the level of noise for each
sample. In general a change in log2 ratio of 0.5 or more
was scored as a change in copy number and a gain in log2
ratio of 2 or more was scored as amplification.
Chi-squared test
The probability of the observed distribution of rearrange-
ments on 8p occurring in the absence of any selection or
pre-disposition to breakage at certain sites was calculated
by chi-squared test. Chromosome 8 was divided into the
major bands (8p11, 12, 21, 22, 23) and the observed
number of rearrangements in each band tested against the
number expected at random according to the size of each
band.
Fluorescence in situ hybridization (FISH)
Metaphase preparation and FISH was carried out as
described previously [10,34]. Chromosome 8 paint was
made using flow sorted chromosomes kindly provided by
Patricia O'Brien and Professor Ferguson-Smith (Univer-
sity of Cambridge, UK). All BACs used for FISH were
tested individually on normal (m62) metaphases for
hybridisation to the correct region of chromosome 8.
FISH on paraffin embedded tumours
Tissue microarray slides were prepared from formalin-
fixed paraffin embedded tissue and analysed according to
the method of Chin et al. [35]. Probes for FISH on paraffin
embedded tumours were prepared in the same way as for
conventional FISH. A pool of three BACs, RP11-529P14
(21.8 Mb; positions are given as BAC midpoints according
to NCBI Build 36), RP11-67H12 (21.9 Mb) and RP11-
70D12 (22.0 Mb), was used for the test region and a pool
of two BACs, RP11-381G11 (19.4 Mb) and RP11-222M11
(19.5 Mb), was used as a reference.
RT-PCR
RNA was reverse transcribed using SuperScript III Reverse
Transcriptase (Invitrogen) and oligo dT primer. Quantita-
tive real-time PCR was carried out, in triplicate, in 10 μl
reactions containing 1× SYBR Green PCR Master Mix
(Applied Biosystems, CA, USA), 2.5 pmol both forward
and reverse gene specific primer and 1 μl of 10-fold
diluted cDNA. Cycling conditions were 50°C for 2 min,
95°C for 10 min then 40 cycles of 95°C for 15 s, 60°C for
1 min and a final dissociation step of 95°C for 15 s, 60°C
for 15 s and 95°C for 15 s in an ABI PRISM 7900 HT
Sequence Detection System (Applied Biosystems).
Primer sequences are given in Additional file 3. Standard
curves for each primer pair were used to calculate amplifi-
cation efficiency coefficients and melting curve analysis
following qPCR confirmed that each primer amplified aPage 3 of 15
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as:
For primary samples expression levels were compared to
the median-expressing tumour. Purified luminal cells,
purified basal cells [36] (both kindly provided by Profes-
sor Mike O'Hare, UCL, London), a range of commercial
normal RNAs (Stratagene (Cambridge, UK), USBiological
(Europa Bioproducts Ltd, Wicken, UK), Ambion
(Huntingdon, UK), BioChain (AMS Biotechnology,
Abingdon, UK), Clontech (Basingstoke, UK)), and nor-
mal breast line HB4a were used as normal controls.
Results
Array CGH results were obtained for a set of 32 breast and
six pancreatic cancer cell lines (Figure 1, Additional files
4). Five cell lines had lost the whole of 8p with respect to
8q, five had no copy number change on 8p, and the
remaining 28 had at least one unbalanced rearrangement
(Additional file 5). By chi-squared analysis the distribu-
tion of breakpoints across the different chromosome
bands was non-random (p = 0.0001), suggesting that rear-
rangements of 8p are under selective pressure or that
breaks occur non-randomly due to breakage-prone
regions. We identified, in addition to the expected trans-
location breakpoints and amplicon in 8p11-12 (29.7 Mb
– centromere), three further regions of recurrent rear-
rangement (Figure 1). These are located more distally on
8p: two overlapping amplicons, which defined a possible
novel region of amplification in 8p21.3 (19.1 Mb – 23.4
Mb), a region of recurrent rearrangement in 8p22 (12.7
Mb – 19.1 Mb) and a region of focal recurrent loss in
8p23.3 (0 Mb – 2.2 Mb). They identify a limited number
of candidate genes in these regions for further study.
Normal copy number polymorphisms were observed at
around 7 Mb in 8p23.1, where there is a high level of seg-
mental duplication and a family of homologous and
highly polymorphic genes, the defensins [37,38]. FISH
with BACs RP11-185K20 (7.80 Mb; positions are given as
BAC midpoints according to NCBI Build 36) and RP11-
43B8 (7.76 Mb) from this region on normal lymphoblas-
toid interphase nuclei confirmed copy number differences
were present between the homologous chromosomes
(Additional file 2).
8p11-12 amplicon
As we described previously, most of the cell lines (25/28)
with rearrangements of 8p had at least one copy number
step in 8p11-12, with loss of most or all of 8p distal to this
region. Similarly, six out of the eight amplicons found
were in the known region of amplification in 8p11-12. A
full analysis of these events is given in Pole et al. [10].
A novel amplicon in 8p21.3
Two cell lines, MDA-MB-134 and BT-20, showed amplifi-
cation in an overlapping region of 8p21.3. This was con-
firmed and the amplicon further mapped by fosmid array
CGH (Figures 2a and 2b, Additional file 6). Both ampli-
cons contained the genes GFRA2 (GDNF Family Receptor
Alpha-2) (21.6 Mb), DOK2 (Docking protein 2) (21.8 Mb),
XPO7 (exportin 7) (21.9 Mb), NPM2 (nucleophosmin/nucle-
oplasmin family member 2) (21.9 Mb) and FGF17 (Fibrob-
last Growth Factor 17) (22.0 Mb). The centromeric edge of
the amplicon in MDA-MB-134 fell within gene EPB49
(Erythrocyte membrane Protein Band 49) (22.0 Mb),
whereas the amplicon in BT-20 extended proximally to
encompass up to a further eighteen genes and one micro
RNA. By both fosmid and BAC array CGH, the amplicon
in BT-20 consisted of two levels of amplification with a
step up at 22.02 Mb (Figure 2a), placing the highest level
of BT-20 amplification outside the MDA-MB-134 ampli-
con.
FISH was used to confirm these amplifications and to
investigate their structure. FISH on BT-20 with BAC RP11-
235B11 (23.0 Mb), from the region of highest amplifica-
tion, and BAC RP11-459H21 (21.2 Mb), from the adja-
cent region of gain, suggested that these two regions of
copy number increase were not co-localised (Figure 2c).
There was one apparently normal chromosome 8 with sig-
nals from both BACs. All extra copies of the region of
highest amplification were found on a single small deriv-
ative chromosome. One copy of the region of lower
amplification was seen on this derivative and one extra
copy was present on a separate derivative chromosome 8.
MDA-MB-134 is known to have an 8p12 amplicon that is
part of a marker chromosome containing co-amplified 8
and 11 sequences [17]. FISH on MDA-MB-134 was carried
out with BAC RP11-135I5 (21.5 Mb), from the 8p21.3
amplicon, and BAC RP11-104D16 (40.2 Mb) from the
8p12 amplicon. This showed that the 8p21.3 amplicon
was intermingled with the 8p12 and 11q13 amplicons on
the der(?)t(8;11)ins(8;11) (Figure 2d). Incidentally, FISH
also showed that the two copies of this marker chromo-
some are not identical but have undergone further evolu-
tion since endoreduplicating. In addition there was one
apparently normal copy of chromosome 8.
Dramatic amplification of the region that was both gained
in BT-20 and amplified in MDA-MB-134 was found in a
single primary breast tumour, out of 98 useable tumour
cores, by FISH on a primary breast tumour tissue microar-
ray, with a pool of BACs positioned within the amplicon
Average Sample Ct for gene  Average reference Ct for gene−( )Amplification Coefficient for gene
Average Sample Ct for GAPDH  Average reference Ct for GAPDH Amplification Co−( ) efficient for GAPDHPage 4 of 15
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to the amplicon (19.3 Mb-19.6 Mb) (Figure 2e).
Expression of the genes within the amplicon, GFRA2,
XPO7, NPM2, FGF17 and EPB49, was analysed to see if
amplification had an effect on expression levels. Quanti-
tative RT-PCR was performed on cDNA from the two cell
lines that had amplification, and a further four cell lines
without amplification in this region (Figure 2f). DOK2
was excluded from quantitative expression studies as
expression was not detectable by conventional PCR in
normal breast line HB4a, BT-20 or MDA-MB-134 (results
not shown). MDA-MB-134 showed over-expression of
GFRA2, XPO7, NPM2 and FGF17 compared to HB4a but
Array CGH of 8p in 38 cancer cell linesFigure 1
Array CGH of 8p in 38 cancer cell lines. The ideogram shows the short arm of chromosome 8 with the position of the 
chromosome bands indicated on the left and regions of recurrent change represented by coloured boxes on the right of the 
ideogram. Previously identified positions of recurrent rearrangement (8p11-12) are indicated by a dashed outline. The novel 
regions identified by this study are indicated by a solid outline. For these summary boxes red indicates a common region of loss 
in 8p23.3, green a common region of gain/amplification in 8p21.3 and white indicates a region with various rearrangements 
including gain, loss and breakpoints in 8p22. Array CGH results are displayed as a heat map using CGHAnalyzer (http://
acgh.afcri.upenn.edu, [64]). The first twenty-four lines show a typical pattern of 8p12 rearrangement with breakpoints, distal 
loss and occasionally proximal amplification. The next four lines have atypical patterns of 8p rearrangement. The final ten lines 
show no copy number changes within 8p but the last five have lost the whole of 8p with respect to 8q. Red, loss relative to the 
ploidy of the cell line; Black, no change; Green, gain; Yellow, high level amplification; Grey, no copy number data; * indicates a 
pancreatic line.
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Analysis of the 8p21.3 ampliconFigure 2
Analysis of the 8p21.3 amplicon. (a) and (b) BAC and fosmid array CGH of the 8p21.3 amplicons in BT-20 and MDA-MB-
134 respectively. (a) BT-20 showed amplification between BAC clones RP11-419L22 (21.13 Mb; positions are given as mid-
points on NCBI Build 36) and RP11-582J16 (22.50 Mb). (b) MDA-MB-134 showed amplification between BAC clones RP11-
458H21 (21.28 Mb) and RP13-600L4 (22.04 Mb). The distal edges of both amplicons fell in a region containing no known genes 
but extended proximally into a gene-dense region. Genes within the overlap are marked. Log2 ratio of the fluorescence inten-
sity is plotted against position on 8p. Grey squares, fosmids; Black diamonds, BACs. (c) FISH of the three chromosomes con-
taining material from the 8p21.3 amplicon in BT-20. Blue, chromosome 8 paint; Green, RP11-459H21 (21.29 Mb); Red, RP11-
235B11 (22.38 Mb). (d) FISH of the three chromosomes containing material from the 8p21.3 and 8p12 amplicons in MDA-MB-
134. Blue, chromosome 8 paint; Green, BAC RP11-135I5 (21.49 Mb); Red, RP11-104D16 (40.25 Mb). (e) FISH of the 8p21.3 
amplicon on a primary breast tumour paraffin section. Red, BAC pool positioned in the amplicon (centred at 21.9 Mb); Green 
(also indicated by arrows), BAC pool distal to the amplicon (centred at 19.5 Mb); Grey, inverted DAPI. (f) Expression levels of 
the five genes included in both the BT-20 and MDA-MB-134 amplicons, shown on the y-axis as a log10 scale of -fold expression 
compared to normal breast cell line HB4a and normalised to GAPDH as an internal control. Expression levels of (g) FGF17 and 
(h) NPM2 in primary tumours and normal controls. Crosses, purified luminal samples; Open circles, possible outliers (value 
more than 1.5× inter-quartile range above the third quartile); Filled circles, outliers (value more than 3× inter-quartile range 
above the third quartile).
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the amplicon falling within this gene (Figure 2f). BT-20
showed marginal, up to 3-fold, over-expression of XPO7
and EPB49. Interestingly, one cell line, DU4475, showed
huge over-expression of NPM2 and FGF17 in the absence
of amplification (Figure 2f).
Since NPM2 and FGF17 were over-expressed in two cancer
cell lines, expression levels were analysed in 61 primary
tumours, from the primary breast tumour series analysed
by FISH, for which cDNA was available (Figures 2g and
2h). However, cDNA was unavailable for the tumour that
showed 8p21.3 amplification by FISH. For both genes,
cDNA made from five commercial normal breast RNAs
showed extreme variation – over 100-fold difference – in
expression across the samples, highlighting the problem
of identifying suitable normal controls for primary
tumour samples. The variation between commercial nor-
mal samples may reflect differences in how they are
obtained, for example if RNA is extracted from tissue
obtained after reduction mammoplasty it may be more
representative of adipocytes than breast epithelium. These
technical concerns may limit the utility of commercially
available normal RNA as a reference. Purified breast lumi-
nal and basal cells [36] were included as further controls
and tended to be more consistent in their expression lev-
els.
None of the tumours expressed FGF17 above the range of
the control groups (Figure 2g). Three tumours expressed
NPM2 at a higher level than any of the commercial con-
trols, although at a lower level than the normal luminal
and basal cells (Figure 2h). Although tumours do not
express either gene outside the range of normal controls,
there are four outliers/probable outliers for each gene,
which have expression at significantly higher levels than
the rest of the tumours (Figures 2g and 2h). Due to the
variability of the normal controls the most significant
observation may be that there were outliers over-express-
ing both genes within the tumour group.
8p22 rearrangements
A cluster of copy number steps that might affect a com-
mon target gene were found between 12.9 Mb and 15.6
Mb in 8p22 (Figure 3a, Additional file 5). Unbalanced
changes in this region were seen in four cell lines:
HCC1806, SUM44, DU4475, and pancreatic line MIA
PaCa-2, which has a homozygous deletion previously
reported by Bashyam et al. ([4]. In addition, we recently
found a reciprocal translocation breakpoint at 14.7 Mb in
HCC1187 by array painting, i.e. hybridisation of individ-
ual chromosomes to arrays [33] (Figure 3a). These rear-
rangements were fine-mapped to a resolution of 0.04 Mb,
by array CGH on a fosmid array covering the three genes
in this region, 13.0 Mb-13.4 Mb (DLC1), 14.0 Mb-14.5
Mb (SGCZ – sarcoglycan zeta) and 15.4 Mb-15.7 Mb
(TUSC3) (Figure 3a, Additional file 6).
In SUM44 there were two copy number steps resulting in
an extra copy of a retained fragment of the region between
13.6 Mb, within the second intron of DLC1 by fosmid
array CGH, and 14.6 Mb, within SGCZ. DU4475 had a
deletion between 15.4 Mb and 15.6 Mb, virtually the
same region as the homozygous deletion in MIA PaCa-2.
The copy number shift observed in DU4475 was relatively
small and FISH, with BAC RP11-314P10 (15.6 Mb)
within the deletion and BAC RP11-480M18 (15.0 Mb)
just outside it, showed that the deletion was only present
on one out of the four copies of chromosome 8 present in
DU4475 cells (Figure 3b).
In HCC1806 two copy number steps fell in this region
(Figure 3a). Comparison of array painting results [33] and
BAC array CGH allowed us to assign these to two separate
copies of chromosome 8. There was a small deletion
between 12.6 Mb and 13.9 Mb, including all of candidate
cancer gene DLC1, on an otherwise normal copy of chro-
mosome 8, and a much larger interstitial deletion
between 14.2 Mb and 31.5 Mb on a del(8)(8p12-22).
Hybridisation of flow-sorted del(8)(8p12-22) to the fos-
mid array pinpointed the distal edge of the deletion to
between 14.19 Mb and 14.24 Mb, within the gene SGCZ
(Figure 3a).
Overall DLC1, the most well characterised tumour sup-
pressor candidate in 8p22, was only affected in a single
cell line by a copy number decrease that included two
other genes. This result is perhaps not surprising as it is
known that DLC1 expression does not correlate with copy
number [39] and, in several tumour types, down-regula-
tion is caused by promoter methylation [40]. In support
of this, DLC1 expression was decreased in 62% (8/13) cell
lines analysed by quantitative PCR, including four lines
without detectable genomic changes in this region (Figure
3c).
In contrast, TUSC3 was affected by two small deletions
that did not include any other gene. TUSC3 showed
decreased expression in these two lines with deletions but
not in any other line (Figure 3c). Anecdotally, TUSC3 also
showed decreased expression in a panel of 61 primary
breast tumours (Figure 3d). This identified six tumours
that had completely lost expression of TUSC3, and a fur-
ther thirteen that expressed it at a lower level than the
range observed in normal breast luminal and basal cells.
Neither the 5' nor the 3' end of SGCZ showed expression
in the lines with copy number changes within it
(HCC1187, SUM44), or model normal breast line HB4a
(results not shown), so it is neither a likely target of dele-Page 7 of 15
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Analysis of 8p22 rearrangementsFigure 3
Analysis of 8p22 rearrangements. (a) Rearrangements between 12.9 Mb and 15.6 Mb in 8p22. Black bar, normal copy 
number for 8p; Grey, heterozygous loss; White with black outline, homozygous loss; White with no outline, breakpoint of 
reciprocal translocation; Black hatching, gain. (b) FISH showing the deletion of the TUSC3 promoter on one of the four copies 
of chromosome 8 in DU4475. Blue, chromosome 8 paint; Green, RP11-480M18 (15.0 Mb); Red, RP11-314P10 (15.6 Mb). (c) 
DLC1 (black bars) and TUSC3 (white bars) expression levels relative to normal breast line HB4a. Note TUSC3 expression is 
decreased in MIA PaCa-2 and DU4475, the two cell lines with deletions of this gene. (d) TUSC3 expression in primary breast 
tumours and various normal breast samples (see Methods). TUSC3 expression is lower in a subset of tumours than in any con-
trol group.
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or insertion breakpoints.
Loss of 8p23.3
Six cell lines showed losses close to the telomere, within
8p23, all including a minimum common region of dele-
tion from 1.7 Mb to 1.9 Mb (Figure 4a). PMC42, HCC38
and HCC1569 had losses from the telomere to 2.2 Mb,
3.4 Mb and 3.7 Mb respectively; HCC1500 had a deletion
between 1.3 Mb and 36.5 Mb; DU4475 had a hetero-
zygous deletion between 1.1 Mb and 1.9 Mb and MIA
PaCa-2 had a homozygous deletion between 1.7 Mb and
1.9 Mb, first reported by Bashyam et al. ([4]. In order to
identify the genes affected by the minimum common
region of loss, the homozygous deletion in MIA PaCa-2
was mapped by PCR. It included exon three, but not exon
2 of CLN8, and all of C8orf61, ARHGEF10 and micro RNA
hsa-mir-596 (Figure 4a).
Since DU4475 had a heterozygous deletion, in order to fit
the classical model of a tumour suppressor gene, we
would expect the remaining copy of the target gene to be
disrupted by some other mechanism, such as point muta-
tion, in this line. Expression data for multiple cancer cell
lines (not shown) suggested ARHGEF10 as a more likely
target gene than CLN8, since ARHGEF10 expression was
decreased by more than 50% in 83% (15/18) of lines
tested. We therefore sequenced ARHGEF10 in DU4475
and found a C → T point mutation in exon 19 (Figure 4b).
This causes a non-conservative histidine to tyrosine sub-
stitution in the protein product at position 733, a highly
conserved region (Figure 4c). Although paired normal
DNA is not available for this cell line this nucleotide
change is not listed as a known SNP (single nucleotide
polymorphism) in the Entrez SNP database (Build 129).
The breast cancer cell line DU4475 was unique in having
five separate small deletions on 8p (Additional file 5), at
least three of which coincided with candidate tumour sup-
pressor genes: a deletion of the promoter of candidate
tumour suppressor TUSC3 (Tumour Suppressor Candidate
3) (15.6 Mb) in 8p22, an approximately 1 Mb deletion
between 21.9 Mb and 23.0 Mb in 8p21, containing candi-
date cancer genes RHOBTB2 (22.9 Mb) and DR5 (Death
receptor 5) (23.0 Mb) [41] but not extending as far as DR4,
and a deletion in 8p23.3, which emerged as a common
region of loss in this study.
Discussion
This high-resolution array CGH study of 8p in carcinomas
has allowed us to build a picture of the more distal events
on 8p and to put each change into context. Previous array
CGH studies have focused on 8p11-12 as a site of recur-
rent translocation and amplification [10,11,14,17,19].
We now present a high-resolution dataset for the whole of
8p with specific follow-up of recurrent events occurring
on distal 8p – a relatively unstudied 30 Mb of DNA.
We identified three novel regions of interest on distal 8p:
8p21.3, which contained a novel amplicon centred at
21.8 Mb; 8p22, which had a variety of rearrangements
between 12.9 Mb and 15.6 Mb; and a region of consistent
loss centred at 1.8 Mb in 8p23.3. These results show that
high-resolution BAC array CGH is a good approach for
characterising genomic rearrangements to a resolution
that provides a manageable number of candidate genes
for further study in a cost-effective way.
Amplification around 21.8 Mb in 8p21.3
A novel amplicon was found in 8p21.3 in both cell lines
and primary tumours. Amplification was a relatively rare
event, seen in 6% (2/41) of cell lines and 1/98 primary
tumours, perhaps due to the reported over-representation
of tumours with amplicons in the cell line collection [19].
However, the presence of the amplicon in primary
tumour material confirms it as a genuine event in breast
cancer. Furthermore, the minimum region of amplifica-
tion contains candidate genes from families known to
play a role in carcinogenesis.
FGF17 (fibroblast growth factor 17) is a member of the
fibroblast growth factor family, a group strongly impli-
cated in carcinogenesis. FGF pathway genes, including
FGF3, FGF4 and FGF8, are common targets of MMTV inte-
gration [42,43] and FGFR3 mutations have been reported
in 41% of bladder cancers [44]. FGF17 is upregulated in
some prostate cancers and this correlates with a higher
risk of metastases and lower survival [45]. NPM2 (Nucle-
ophosmin/nucleoplasmin member 2) can catalyse the
assembly of DNA and histones into nucleosomes and is
involved in decondensation and remodelling of sperm
chromatin immediately after fertilisation. In the same
family, NPM1 has the ability to regulate the function of
the tumour suppressor protein ARF [46], and is mutated
in several haematological malignancies including 35% of
acute myeloid leukaemias [47,48]. GFRA2 mediates RET
signalling in response to the ligand GDNF [49]. RET is a
well-known oncogene that plays a role in the develop-
ment of thyroid carcinomas and the familial cancer syn-
drome multiple endocrine neoplasia (reviewed in [50]).
Of these genes FGF17 and NPM2 showed over-expression
in two cell lines, one with (MDA-MB-134), and one with-
out (DU4475), amplification. However, neither was over-
expressed in the second cell line with amplification in this
region (BT-20). If, as the array CGH data suggests, the
highest level of amplification in BT-20 lies outside the
region amplified in MDA-MB-134, there may be multiple
targets of amplification in this region. A similarly complex
pattern of non-overlapping amplicon peaks is seen inPage 9 of 15
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Analysis of losses in 8p23.3Figure 4
Analysis of losses in 8p23.3. (a) Losses between 3.7 Mb and the telomere. Black bar, normal copy number for 8p; Grey, 
heterozygous loss; White with black outline, homozygous loss. Black arrows, position of primer pairs that amplify a product 
from MIA PaCa-2 genomic DNA i.e. lie outside the homozygous deletion; Grey arrows, position of primer pairs that do not 
amplify a product from MIA PaCa-2 genomic DNA. (b) Sequencing trace showing the point mutation in exon 19 of 
ARHGEF10. The normal sequence has a cytosine at the position indicated by the arrow. (c) Conservation of ARHGEF10. Yel-
low, the residue that is converted from a histidine to tyrosine by the point mutation in DU4475; Grey, conserved residues.
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gestion that they contain as many as four targets [11,51].
Rearrangements between 12.9 Mb and 15.6 Mb in 8p22
SGCZ (14.6 Mb), although disrupted by two unbalanced
changes and one balanced translocation breakpoint, is
unlikely to be a cancer gene. It forms part of the sarcogly-
can complex that links the intracellular cytoskeleton to
the extracellular matrix in muscle [52], and our findings
show that it is not expressed, either in normal breast or as
a consequence of rearrangement. Although DLC1 (13.2
Mb) has a tumour suppressive effect in a variety of tumour
types, including breast cancer (e.g. [40]), it was not a
likely target of these 8p22 rearrangements as it lay just
outside the rearrangements in all except one case. This is
consistent with suggestions that genomic rearrangement
is not a mechanism of DLC1 inactivation [39]. If a tumour
suppressor gene is present in this region, then TUSC3
(15.6 Mb), previously suggested as a potential target in
this region ([4,53,54], was the strongest candidate target
of the rearrangements of 8p22 in this study. Two cell lines
have deletions that solely affect TUSC3 and result in
decreased expression and expression was lost or decreased
in 31% of primary breast tumours. However, the presence
of several breakpoints in this region that do not appear to
have an effect at the gene level could alternatively suggest
that this site is prone to breakage.
Losses between 1.0 Mb and 2.1 Mb in 8p23.3
Loss of 8p23.3, with a minimum common region of
between 1.7 Mb and 1.9 Mb, was found in both breast and
pancreatic cell lines, consistent with evidence from LOH
studies of a cancer gene situated between 1.0 Mb and 2.1
Mb. 1 Mb array CGH data [55] from primary breast
tumours suggests that 8p23.3 is a genuine target in pri-
mary tumours. 8% (6/73) of tumours may have specific
loss distal to 10 Mb. However, analysis of that dataset is
difficult due to the low resolution and the effect of con-
taminating normal DNA on log2 ratio shifts in primary
material. In combination, these results suggest the region
between 1.0 Mb and 2.1 Mb as the location of a tumour
suppressor gene. The genes affected by the minimum
common region of deletion, and therefore candidates, are
CLN8, C8orf61, has-mir-596 and ARHGEF10. ARHGEF10
has emerged as a candidate colorectal cancer gene in the
sequencing screen carried out by Wood et al. [56], and, in
conjunction with our discovery of a heterozygous deletion
of ARHGEF10 in DU4475 with mutation of the remaining
copy, this makes it a strong candidate for the 8p23.3
tumour suppressor. Functional data about ARHGEF10
supports a role for it in carcinogenesis. It activates RhoB
[57], which is down-regulated in multiple tumour types
[58,59] and is necessary for apoptosis in response to DNA
damage in transformed cells [60].
A parsimonious model to explain 8p rearrangements
A large number of cancers lose all, or nearly all of 8p,
potentially suggesting the presence of tumour suppressor
loci, while the occurrence of specific rearrangements on
distal 8p supports the theory that there are multiple cancer
genes located on 8p. Many previous LOH and copy
number studies, as well as our data, especially the specifi-
city of the deletions in DU4475, can narrow down the
regions of loss to 8p22 and 8p23; we suggest TUSC3 and
ARHGEF10 as possible targets of genomic rearrangement.
There may well be other tumour suppressor genes, such as
DLC1, located on 8p but these appear to be inactivated by
alternative mechanisms, including methylation. These
results lead us to suggest a parsimonious model to explain
the varied rearrangements seen on 8p in cancer (Figure 5)
The most frequent rearrangements are loss of distal 8p,
from 8p12 to the telomere, sometimes with proximal
amplification of 8p11-12. As previously suggested, unbal-
anced translocations through 8p11-12 can be explained
by the presence of a major tumour suppressor gene at the
most distal of these breaks, around 30 Mb [10]. However,
we argue that if this were the only tumour suppressor gene
on 8p, we might expect to see a mirror-image pattern of
breaks distal to this gene with the telomeric sequences
being retained, as well as interstitial deletions of the
tumour suppressor gene. A tendency towards loss of the
whole of distal 8p suggests that there is at least one further
tumour suppressor gene, and that it is located close to the
telomere (Figure 5). This is consistent with our data sug-
gesting a tumour suppressor gene is located in 8p23.3.
There can therefore also be any number of additional
tumour suppressor genes in between these two which
would give the same pattern of rearrangement, and our
data suggests that there may be at least one further candi-
date gene located in 8p22. In line with the application of
Occam's razor loss of both/all of these tumour suppressor
genes is most often seen as loss of the whole of distal 8p,
but can also be achieved by several more specific events,
therefore explaining the complex and inconsistent pattern
of changes on distal 8p (Figure 5) – tumours may have
deletions of varying sizes encompassing two or more
tumour suppressor genes as well as losing them all by loss
of the whole of 8p or a proximal translocation.
Cell lines with multiple small deletions are invaluable in
allowing us to narrow down the number and position of
tumour suppressor genes on 8p. The unique pattern of
deletions in DU4475, three of which target candidate
tumour suppressor genes or regions previously reported as
frequently deleted, supports 8p23.3, 8p22 and 8p21 as
candidate regions. Potential targets in 8p23.3 and 8p22
have been discussed above while 8p21, although only
affected by a single small deletion in this study, is the loca-
tion of RHOBTB2, a candidate breast cancer gene basedPage 11 of 15
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TRAIL receptors DR4 and DR5, which have been suggested
as candidate cancer genes owing to their pro-apoptotic
function [61]. MIA PaCa-2 has two deletions on 8p, also
supporting the existence of tumour suppressor genes at
8p22 and 8p23.3.
Although the premise of our Discussion is that the driving
force behind 8p rearrangements is selection for the altera-
tion of cancer genes, the same pattern of rearrangements
might be observed if the driving force was the mechanism
of breakage e.g the presence of fragile sites on 8p. For
example, the breaks at 8p12 with proximal amplification
could be due to the presence of a fragile site that initiates
breakage-fusion-bridge cycles [62] although no fragile site
has been shown to exist on 8p [63] and 8p12 breaks fre-
quently occur without accompanying amplification.
Conclusion
While early work on 8p, driven by LOH analysis [6,7]
focused on distal 8p, more recent studies have concen-
trated on 8p11-12 [10,11] in an attempt to explain the
role of this chromosome arm in cancer. This present study
suggests that, in addition to the frequently observed loss
from 8p12 to the telomere with proximal amplification,
there are additional rarer events that occur on distal 8p.
While loss of specific distal loci may occur in only a few
cases, loss of these distal sequences may also add to selec-
tion for general distal loss following the commonly
observed breakage at 8p12 in many tumours.
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A parsimonious model of 8p rearrangementsFigu e 5
A parsimonious model of 8p rearrangements. The different patterns of 8p rearrangement that would be expected in a 
sample of tumours based on the number and position of tumour suppressor genes (not to scale). Top is the pattern of rear-
rangements expected if there is a single tumour suppressor gene located in 8p12. Middle is the pattern of rearrangements pre-
dicted if there were at least two tumour suppressor genes located on 8p, one in 8p12 and one located close to the telomere in 
8p23.3. This fits the common overall pattern of breaks in 8p12 with loss of distal 8p. Bottom is a representation of some of the 
atypical 8p rearrangements found in cancer cell lines including DU4475, HCC1500 and PMC42. These can be explained by the 
presence of other tumour suppressor genes in between those in 8p12 and 8p23.3; our results suggest at least one, at 8p22. 
Since each of these tumour suppressor genes is only lost in a proportion of cases a complex pattern of rearrangements encom-
passing some or all of these regions results. Loss of the whole of distal 8p will be the most common rearrangement as it 
removes all tumour suppressor genes as the result of a single event.
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